stockportfolio.pro
Stocks / AVTR vs KYMR
AVTR vs KYMR
Avantor, Inc. and Kymera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Avantor, Inc. (AVTR) | Kymera Therapeutics, Inc. (KYMR) | |
|---|---|---|
| Market cap | $6.6B | $6.7B |
| Revenue (latest FY) | $6.55B | $39.21M |
| Net income (latest FY) | $-530.20M | $-311.35M |
| Revenue growth (5y CAGR) | 0.5% | 2.9% |
| Net margin | -8.1% | -794.0% |
| Return on equity | -9.5% | -19.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 6 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVTR — free Open KYMR — freeFrequently asked questions
Which is bigger, AVTR or KYMR?
Kymera Therapeutics, Inc. is larger by market capitalization — $6.7B versus $6.6B.
Which grows faster, AVTR or KYMR?
Over the last five fiscal years, Kymera Therapeutics, Inc. grew revenue faster — 2.9%/yr versus 0.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.